PUBLISHER: The Business Research Company | PRODUCT CODE: 1942510
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942510
Cancer supportive care products encompass a range of medical treatments, therapies, and products designed to manage and alleviate the symptoms, side effects, and complications associated with cancer and its treatments. These products aim to enhance the quality of life for cancer patients by providing physical, emotional, and psychological support.
Key categories of drugs in cancer supportive care include nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infective drugs, anti-emetics, monoclonal antibodies, erythropoietin-stimulating agents, opioid analgesics, bisphosphonates, and granulocyte colony-stimulating factors. NSAIDs, for example, help reduce inflammation, pain, and fever by inhibiting enzymes involved in the inflammatory process, which assists in managing pain and discomfort related to cancer and its treatments. These products are used for various types of cancer, including lung, breast, prostate, liver, bladder, leukemia, ovarian, and melanoma cancers. They are distributed through hospital pharmacies, retail pharmacies, and compounding pharmacies.
Tariffs have influenced the cancer supportive care products market by increasing costs for imported active pharmaceutical ingredients and finished formulations used across analgesics, anti-emetics, and biologics. These cost pressures have affected pricing and supply consistency, particularly in drug classes such as monoclonal antibodies and granulocyte colony stimulating factors, with asia-pacific and north america being most impacted due to global sourcing dependencies. To offset these effects, manufacturers are strengthening local manufacturing and regional supply chains. In some markets, tariffs have supported domestic pharmaceutical production and improved supply security over the long term.
The cancer supportive care products market research report is one of a series of new reports from The Business Research Company that provides cancer supportive care products market statistics, including cancer supportive care products industry global market size, regional shares, competitors with a cancer supportive care products market share, detailed cancer supportive care products market segments, market trends and opportunities, and any further data you may need to thrive in the cancer supportive care products industry. This cancer supportive care products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cancer supportive care products market size has grown steadily in recent years. It will grow from $22.47 billion in 2025 to $23.54 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to rising global cancer prevalence, increasing use of chemotherapy and radiation therapy, growing incidence of treatment-related side effects, expansion of hospital-based oncology services, improved access to essential supportive drugs.
The cancer supportive care products market size is expected to see steady growth in the next few years. It will grow to $28.24 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to aging population with higher cancer risk, rising focus on patient-centric oncology care, increasing awareness of supportive care benefits, expanding cancer treatment volumes globally, growing demand for long-term symptom management. Major trends in the forecast period include growing demand for comprehensive symptom management therapies, increasing focus on quality-of-life-oriented cancer care, rising adoption of multimodal supportive drug regimens, expansion of supportive care across multiple cancer indications, increasing integration of supportive care in standard oncology protocols.
The growing incidence of cancer is expected to drive the expansion of the cancer supportive care products market in the future. As populations age, the risk of cancer increases due to cellular changes and prolonged exposure to various risk factors. Additionally, lifestyle factors such as smoking, poor diet, insufficient physical activity, and excessive alcohol consumption contribute significantly to cancer risk. Cancer supportive care products are designed to manage symptoms, enhance quality of life, and support patients undergoing treatment, addressing the increasing need due to the rising cancer rates. For example, in January 2024, the American Cancer Society, a US-based non-profit organization focused on cancer elimination, projected 58,450 cases of oral cavity and pharynx cancer, marking a 7.2% increase from the 54,540 cases reported in 2023. Consequently, the rising incidence of cancer is expected to propel the growth of the cancer supportive care products market.
Major companies operating in the cancer supportive care products market are concentrating on mechanical-action oral mucosal protective gels, such as Gelclair, to reduce therapy-induced oral mucositis in patients receiving chemotherapy or radiotherapy. Mechanical-action oral mucosal protective gels are products that form a physical coating over the oral mucosa, helping to relieve pain and discomfort without anesthetic or numbing effects, thereby supporting patients' ability to eat, drink, and swallow during cancer treatment. For instance, in October 2024, Jaguar Health, a U.S.-based biopharmaceutical company, introduced Gelclair, a prescription gel for the management of oral mucositis. Gelclair binds to the oral mucosa to create a protective barrier, delivers rapid and sustained pain relief, and enhances comfort during eating and swallowing without causing stinging or numbness in the mouth.
In October 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired POINT Biopharma Global Inc. for an undisclosed sum. This acquisition aims to enhance Eli Lilly's capabilities in targeted radiopharmaceuticals for cancer treatment. POINT Biopharma Global Inc., a US-based biotechnology company, focuses on developing and commercializing radiopharmaceuticals for targeted cancer therapies.
Major companies operating in the cancer supportive care products market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Limited, Baxter International Inc., Daiichi Sankyo Company Limited, Kyowa Hakko Kirin Co. Ltd., Exelixis Inc., Fagron Group B.V., Tessa Therapeutics Pte Ltd., APR Applied Pharma Science Research S.A., Acacia Pharma Ltd., Helsinn Healthcare SA, Kyowa Kirin International PLC, OncoGenex Pharmaceuticals Inc., Celgene Corporation, Astellas Pharma Inc.
North America was the largest region in the cancer supportive care products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care products market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cancer supportive care products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cancer supportive care products market consists of sales of medications, nutritional supplements, pain management products, and therapeutic devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cancer Supportive Care Products Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cancer supportive care products market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cancer supportive care products ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer supportive care products market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.